Barclays PLC United Therapeutics Corp Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in United Therapeutics Corp stock. As of the latest transaction made, Barclays PLC holds 58,594 shares of UTHR stock, worth $20.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

58,594

Previous 58,594 -0.0%

Holding current value

$20.9 Million

Previous $21 Million -0.0%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$311.04 - $363.55 $4.8 Million - $5.62 Million	-15,445 Reduced 20.86%	58,594 $21 Million
Q2 2024 Aug 14, 2024	SELL	$228.26 - $319.04 $3.84 Million - $5.37 Million	-16,832 Reduced 18.52%	74,039 $23.6 Million
Q1 2024 May 15, 2024	SELL	$210.76 - $249.51 $3.41 Million - $4.04 Million	-16,201 Reduced 15.13%	90,871 $20.9 Million
Q4 2023 Feb 15, 2024	BUY	$214.88 - $256.94 $2.52 Million - $3.02 Million	11,750 Added 12.33%	107,072 $23.5 Million
Q3 2023 Nov 07, 2023	BUY	$211.82 - $248.24 $1.46 Million - $1.72 Million	6,915 Added 7.82%	95,322 $21.5 Million
Q2 2023 Aug 03, 2023	BUY	$205.19 - $232.99 $9.18 Million - $10.4 Million	44,715 Added 102.34%	88,407 $19.5 Million
Q1 2023 May 04, 2023	BUY	$212.99 - $276.17 $2.75 Million - $3.57 Million	12,931 Added 42.04%	43,692 $9.79 Million
Q4 2022 Feb 13, 2023	SELL	$205.95 - $280.43 $5.8 Million - $7.9 Million	-28,181 Reduced 47.81%	30,761 $8.55 Million
Q3 2022 Nov 03, 2022	BUY	$203.3 - $244.17 $8.1 Million - $9.73 Million	39,850 Added 208.73%	58,942 $12.3 Million
Q2 2022 Aug 12, 2022	SELL	$174.81 - $241.14 $144,043 - $198,699	-824 Reduced 4.14%	19,092 $4.5 Million
Q1 2022 May 16, 2022	BUY	$166.16 - $213.96 $805,211 - $1.04 Million	4,846 Added 32.16%	19,916 $3.57 Million
Q4 2021 Feb 14, 2022	SELL	$184.32 - $216.08 $8.35 Million - $9.79 Million	-45,308 Reduced 75.04%	15,070 $3.26 Million
Q3 2021 Nov 09, 2021	BUY	$179.86 - $214.88 $3.64 Million - $4.35 Million	20,259 Added 50.5%	60,378 $11.1 Million
Q2 2021 Aug 13, 2021	BUY	$170.47 - $211.93 $4 Million - $4.98 Million	23,493 Added 141.3%	40,119 $7.2 Million
Q1 2021 May 13, 2021	BUY	$153.94 - $174.85 $1.47 Million - $1.67 Million	9,579 Added 135.93%	16,626 $2.78 Million
Q4 2020 Feb 11, 2021	SELL	$101.87 - $151.79 $280,753 - $418,333	-2,756 Reduced 28.11%	7,047 $1.07 Million
Q3 2020 Nov 12, 2020	SELL	$99.9 - $121.13 $602,097 - $730,050	-6,027 Reduced 38.07%	9,803 $992,000
Q2 2020 Aug 12, 2020	SELL	$92.74 - $125.82 $132,710 - $180,048	-1,431 Reduced 8.29%	15,830 $1.92 Million
Q1 2020 May 13, 2020	SELL	$79.39 - $115.35 $13.8 Million - $20.1 Million	-173,988 Reduced 90.97%	17,261 $1.64 Million
Q4 2019 Feb 10, 2020	BUY	$78.31 - $95.34 $13.9 Million - $16.9 Million	177,195 Added 1260.82%	191,249 $16.8 Million
Q3 2019 Nov 14, 2019	SELL	$74.85 - $85.99 $1.43 Million - $1.64 Million	-19,073 Reduced 57.58%	14,054 $1.12 Million
Q2 2019 Aug 14, 2019	BUY	$76.06 - $120.81 $957,671 - $1.52 Million	12,591 Added 61.31%	33,127 $2.59 Million
Q1 2019 May 15, 2019	SELL	$107.15 - $126.84 $205,728 - $243,532	-1,920 Reduced 8.55%	20,536 $2.41 Million
Q4 2018 Feb 14, 2019	SELL	$101.4 - $128.73 $1.71 Million - $2.18 Million	-16,904 Reduced 42.95%	22,456 $2.44 Million
Q3 2018 Nov 14, 2018	BUY	$113.81 - $129.46 $1.79 Million - $2.04 Million	15,749 Added 66.7%	39,360 $5.03 Million
Q2 2018 Aug 14, 2018	SELL	$101.14 - $118.31 $1.56 Million - $1.82 Million	-15,391 Reduced 39.46%	23,611 $2.67 Million
Q1 2018 May 15, 2018	SELL	$107.21 - $151.94 $390,029 - $552,757	-3,638 Reduced 8.53%	39,002 $4.38 Million
Q4 2017 Feb 14, 2018	SELL	$118.58 - $151.28 $2.34 Million - $2.98 Million	-19,708 Reduced 31.61%	42,640 $6.31 Million
Q3 2017 Nov 14, 2017	BUY	$114.6 - $136.81 $7.15 Million - $8.53 Million	62,348	62,348 $7.31 Million

Others Institutions Holding UTHR

# of Institutions

672

Shares Held

42.3M

Call Options Held

194K

Put Options Held

295K

View Full List

About UNITED THERAPEUTICS Corp

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.2B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

More about UTHR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account